Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia

References

• Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.
   PubMed Web of Science ®Google Scholar
• Printz C. Recurrence, poor survival more likely in patients with acute myeloid leukemia who have certain mutations. Cancer. 2015;121:4275.
   Web of Science ®Google Scholar
• Tsai CT, So CW. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene. 2017;36:1753–1759.
   PubMed Web of Science ®Google Scholar
• Sasine JP, Schiller GJ. Acute myeloid leukemia: how do we measure success? Curr Hematol Malig Rep. 2016;11:528–536.
   PubMed Web of Science ®Google Scholar
• Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324: 1670–1673.
   PubMed Web of Science ®Google Scholar
• Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16:559–562.
   PubMed Web of Science ®Google Scholar
• Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci. 2005;1044:1–5.
   PubMed Web of Science ®Google Scholar
• Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34+/CD38− progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 2000;60:4403–4411.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307.
   PubMed Web of Science ®Google Scholar
• Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 2015;125:2630–2640.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129: 1627–1635.
   PubMed Web of Science ®Google Scholar
• Riccioni R, Rossini A, Calabro L, et al. Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain. Leuk Lymphoma. 2004;45:1511–1517.
   PubMed Web of Science ®Google Scholar
• Cerny J, Yu H, Ramanathan M, et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013;160:262–266.
   PubMed Web of Science ®Google Scholar
• Sarry JE, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 2011;121:384–395.
   PubMed Web of Science ®Google Scholar
• Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105:549–557.
   PubMed Web of Science ®Google Scholar
• Hwang K, Park CJ, Jang S, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol. 2012;91:1541–1546.
   PubMed Web of Science ®Google Scholar
• Tomonaga M. [Outline and direction of revised WHO classification of Tumors of Haematopoietic and Lymphoid Tissues]. Rinsho Ketsueki. 2009;50: 1401–1406. Japanese.
   PubMedGoogle Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116: 354–365.
   PubMed Web of Science ®Google Scholar
• Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica. 2016;101:1351–1358.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia: 2016 update on risk-stratification and management. Am J Hematol. 2016;91:824–846.
   PubMed Web of Science ®Google Scholar
• Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1–7.
   PubMedGoogle Scholar
• Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. J Clin Lab Anal. 1999;13: 19–26.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3: 730–737.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–1784.
   PubMed Web of Science ®Google Scholar
• Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2:4.
   PubMedGoogle Scholar
• Padros MR, Salamone MC, Zunszain PA, et al. Differential expression of CD25 and HC2 antigens on subtypes of acute myeloid leukemias. Eur J Haematol. 1989;42:436–440.
   PubMed Web of Science ®Google Scholar
• Gonen M, Sun Z, Figueroa ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;120:2297–2306.
   PubMed Web of Science ®Google Scholar
• Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104: 11008–11013.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu P, Yao D, et al. CD33, CD96 and death associated protein kinase (DAPK) expression are associated with the survival rate and/or response to the chemotherapy in the patients with acute myeloid leukemia (AML). Med Sci Monit. 2017;23:1725–1732.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra9.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia 2016;30:439–446.
   PubMed Web of Science ®Google Scholar
• Garg S, Ghosh K, Madkaikar M. Antigen expression on a putative leukemic stem cell population and AML blast. Int J Hematol. 2016;103:567–571.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587.
   PubMed Web of Science ®Google Scholar